About this trial
The purpose of this surveillance (non-interventional) clinical study is to genotype the causative agents of rickettsioses in biological samples of patients from the regions of Russia. This is a solely observational study in the patients with diagnosed or suspected tick-borne rickettsioses, with no intervention to the routine treatment and diagnostic process. During the study the medical history, diseases progress and symptoms, as well as treatments are being registered in individual case report forms. The rests of the samples used for standard diagnostics (blood, plasma, buffy coat, or serum, and/or swab of the eschar) are being collected and afterwards analyzed for rickettsial genotypes. These data are being compared to the medical history and symptoms of the patients in order to identify clinical patterns specific for causative agents of rickettsioses. Informed consent from all patients or their legal representatives are being collecting. The study was approved by the ethical committee.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Written informed consent by the subject (or their legal representative) to participate in the study;
Disqualifiers
None
Trial population
Male and female patients of any age with diagnosed or suspected tick-born rickettsioses.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Genetic identification of the rickettsia species
Genetic identification of the rickettsia species causing rickettsioses, including new circulating genotypes
Sponsors and contacts
Click on the lead sponsor to view all of their trials.